{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-003326","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.542244+00:00","generated_at":"2026-06-25T23:45:01.509380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Corvus Pharma Q1 net loss $8.3M; cash $62.9M; Phase 2 NSCLC trial planned","bullets":["Net loss $8.3M for Q1 2022 vs $11.6M in Q1 2021; R&D expenses down to $5.1M from $8.2M.","Cash, cash equivalents and marketable securities $62.9M as of March 31, 2022 vs $69.5M at Dec 31, 2021.","Plans Phase 2 randomized trial of mupadolimab + chemo in front-line NSCLC in 2022 with ~150 patients.","Phase 1b/2 ciforadenant + ipilimumab/nivolumab in front-line RCC to start Q3 2022 via Kidney Cancer Consortium.","Phase 1/1b CPI-818 (ITK inhibitor) continues enrolling T-cell lymphoma patients; data expected later 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-003326","json":"https://secwatch.observer/filing/0001171843-22-003326.json","markdown":"https://secwatch.observer/filing/0001171843-22-003326.md","text":"https://secwatch.observer/filing/0001171843-22-003326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184322003326/0001171843-22-003326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184322003326/f8k_050522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:45:01.509380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}